Adam Feuerstein on Muck Rack

Adam Feuerstein Verified

As seen in:  The Street, The Street
Is this you? Contact us to claim or edit this page

Sr. Columnist at TheStreet, aka the Col. Jessup of biotech/drug stocks. Data Are. I curse. Said one analyst: The likes of Adam Feuerstein attack viciously.

Regulus Gets Seat at Hep C Table With Today's Impressive Drug Results — A single injection of a microRNA therapeutic directed at a genetic target in the liver of hepatitis C patients produced a significant drop in viral load, according to interim results from an early-stage study announced Wednesday by Regulus Therapeutics , the developer of the therapy, known as RG-101.

Speculating on Achillion's Boom-or-Bust Hep C Drug Study Results — Yesterday afternoon, I posed the following question about Achillion Pharmaceuticals and its hepatitis C "nuc" ACH-3422 to the biotech Twitter-verse: For those not obsessed with the clinical development of hepatitis C drugs (what's wrong with you?) -- My question refers to the imminent announcement of results from a phase I "proof of concept" study of '3422 in treatment-naive genotype 1 patients.

First Detailed Look at Celgene Crohn's Disease Pill Impresses — The first look at Celgene's experimental Crohn's disease drug GED-0301 is impressive and explains why company executives have been so bullish on the drug since acquiring it last spring for big bucks. As a pill, GED-031 (also known as mongersen) has the potential to become a preferred Crohn's therapy over injectable drugs like Abbvie's top-selling Humira.

Biotech Stock Mailbag: Small-Cap Rebound, Avanir, Ohr, CytoSorbents — BOSTON ( TheStreet) -- This week's Biotech Stock Mailbag opens with a question about the strong performance of small-cap stocks in what has otherwise been a down week. @adamfeuerstein hey Adam that rise of 6% last 2 days in $ARNA must be because people took money out of $NFLX that makes sense does it not?

Brainstorm CEO Offers Investors a Frank Outlook for ALS Therapy — NEW YORK ( TheStreet) -- Halfway through my two-hour phone conversation with Tony Fiorino last week, I asked the health care hedge fund investor-turned-CEO of Brainstorm Cell Therapeutics why he chose to leave Wall Street to run a tiny and risky stem-cell therapy company. Brainstorm's challenges are particularly daunting.

Gilead Sciences Weak Today on Hep C Drug Price Concerns, Tax Loophole Closure — Stocks in this article: GILD It's one thing for small-cap biotech stocks to trade horribly, but healthcare investors take notice when shares of Gilead Sciences , one of the sector's biggest and best performers, take a turn south.

Sarepta Drug Could Benefit From Duchenne Muscular Dystrophy Patient Study — BOSTON ( TheStreet) -- A newly published study following the progression of Duchenne muscular dystrophy (DMD) patients for three years supports Sarepta Therapeutics' argument the benefit observed in its small eteplirsen study is real. For investors, that means there's a strong likelihood Sarepta will seek accelerated approval for the drug next year.

Gilead Sciences Wins FDA Approval for New Harvoni Hepatitis C Pill — Gilead Sciences has secured U.S. approval for Harvoni, a new combination hepatitis C therapy, according to an announcement from the U.S. Food and Drug Administration. Harvoni is a single, once-daily pill combining Gilead's existing blockbuster hepatitis C medicine Sovaldi (sofosbuvir) with a newer drug ledipasvir.

Biotech Stock Mailbag: Keryx, Puma, Gilead, Arrowhead and Hate Mail Galore! — BOSTON ( TheStreet) -- Welcome back to another Biotech Stock Mailbag. Let's get to your emails and tweets. @adamfeuerstein when KERX gets NCE status are you going to print a retraction? - OnFireSports (@onfiresports3) October 2, 2014 Sure, if FDA awards New Chemical Entity (NCE) status to Keryx Pharma's kidney dialysis phosphate binder "We Can't Call It Zerenex," I will most certainly admit my error.

Medicare Recommends $500 Reimbursement for Exact Sciences' Colon Cancer Test — MADISON, Wis. ( TheStreet) -- Medicare officials are recommending a $502 reimbursement for Exact Sciences' Cologuard colon cancer screening test, according to a preliminary payment report issued Thursday night. If confirmed later this year, the $502 price for each Cologuard test is a big win for Exact Sciences because it means Medicare gave the company everything asked for during reimbursement negotiations.
More Articles →
Oct 22, 2014

I’ve been receiving fresh-roasted beans from @driftawaycoffee for 2 months, couldn’t be happier w/ quality & service. Excellent.

Oct 22, 2014

$ADHD - New MDX ph3 slide deck —>… They did some serious data mining. Yowza.

Oct 22, 2014

. @RobTheStreet @TheStalwart Better hed: “OMG You Guys, This Is The Most Important Chart During My Time At Business Insider"

Oct 22, 2014

@DewDiligence You know, sitting at the children’s table can be fun, too.

Oct 22, 2014

Even when @MarkSchoenebaum is destroying the credibility of the doc on his $CELG mongersen call y’day, he’s polite and charming.

Oct 22, 2014

@Sport234a BASHER!!! I’m reporting you to Steven Pearlstein and CREW.

Oct 22, 2014

RT @MelissaLeeCNBC: $RGLS +105% TODAY- proposed Hep C treatment showed positive results. CEO & @megtirrell joins @CNBCFastMoney 5p in EXCLU…

Oct 22, 2014

For those w/ access, @MarkSchoenebaum 6 expectations for $AMGN analyst mtg underscore why the stock is boring to write about.

Oct 22, 2014

@natesadeghi You need some siracha or green chili salsa on top of that egg.

Learn how to connect with Adam on social media by joining Muck Rack Pro

Are You a Journalist?

Make a Portfolio

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.

Share This Profile